Table 3 Response by treatment combination
From: Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
Response | |||||
|---|---|---|---|---|---|
Treatment combination | CR | PR | SD | PD | NE |
Cetuximab monotherapy | - | 1 | - | 1 | - |
Cetuximab+FU+Leucovorin+CPT-11 | - | 11 | 7 | 7 | 2 |
Cetuximab+FU+Leucovorin+Eloxatin | - | 7 | 2 | 8 | 1 |
Cetuximab+CPT-11+Eloxatin | - | - | 1 | 1 | 2 |
Cetuximab+CPT-11+Capecitabine | - | - | 1 | 2 | 1 |
Cetuximab+Eloxatin+Capecitabine | - | 2 | 2 | - | - |
Cetuximab+CPT-11 | 2 | 2 | 2 | 7 | - |
Cetuximab+Eloxatin | - | - | - | - | 1 |
- | - | - | 1 | - | |
- | - | 1 | - | - | |
Cetuximab+FU+CPT-11 | - | 1 | - | - | - |
Cetuximab+FU+Leucovorin | - | - | 1 | 1 | - |
Cetuximab+CPT-11+Avastin | - | - | - | 1 | - |
Cetuximab+Capecitabine | - | - | - | 1 | 2 |
Total | 2 | 24 | 17 | 30 | 9 |